Enzeevu (Aflibercept-Abzv) for AMD

Overview
Enzeevu is approved by the U.S. Food and Drug Administration (FDA) for the treatment of neovascular (wet) age-related macular degeneration (AMD). It is prescribed for individuals with AMD to slow vision loss caused by the abnormal growth of blood vessels in the retina. Enzeevu is a biosimilar to Eylea (aflibercept), meaning it is highly similar to Eylea with no clinically meaningful differences in safety or effectiveness. Enzeevu is also known by its drug name, aflibercept-abzv.

As a vascular endothelial growth factor (VEGF) inhibitor, Enzeevu works by blocking VEGF proteins, which play a key role in the formation of abnormal blood vessels in the eye. By inhibiting these proteins, Enzeevu helps reduce fluid buildup and prevents further damage to the retina.

How do I take it?
Prescribing information states that Enzeevu is administered by intravitreal injection (injection into the eye). The recommended dosage schedule is every four weeks (approximately every 28 days) for the first three months. After the initial three-month period, the injection is typically administered once every eight weeks. In some cases, a person may require more frequent injections every four weeks after the first 12 weeks. The drug should be administered exactly as prescribed by a health care provider.

Side effects
Common side effects of Enzeevu include conjunctival hemorrhage (bleeding under the conjunctiva of the eye), eye pain, cataract, vitreous detachment (separation of the vitreous gel from the retina), vitreous floaters (small shapes that appear in your vision), and increased intraocular pressure (pressure inside the eye).

Rare but serious side effects may include endophthalmitis (inflammation inside the eye), retinal detachment, and retinal vasculitis (inflammation of the retinal blood vessels) with or without occlusion (blockage). There is also a potential risk of arterial thromboembolic events (blood clots in arteries) following intravitreal injections.

For more information about this treatment, visit:

Enzeevu — Drugs.com

Enzeevu (Aflibercept-Abzv) Injection, for Intravitreal Use — U.S. Food and Drug Administration